Covid-19: Panel for nod to P-2/3 vaccine trials for 2-17-year-olds | India News

NEW DELHI: An expert panel of India’s Central Drug Authority on Tuesday recommended granting permission to Serum Institute of India for conducting phase 2/3 trials of Covid vaccine Covovax on kids aged 2 to 17 years with certain conditions, official sources said. The trials would cover 920 children, 460 each in the age-group of 12-17 and 2-11 across 10 sites.
“The Subject Expert Committee on Covid-19 deliberated on the revised study protocol application given by SII on Tuesday and recommended granting permission to the firm for conducting phase 2/3 trial of Covovax on kids aged 2 to 17 years,” a source said.
FacebookTwitterLinkedinEMail

Related Keywords

India , ,Expert Committee On Covid ,India Central Drug Authority On ,Serum Institute Of India ,Central Drug Authority ,Serum Institute ,Subject Expert Committee ,இந்தியா ,இந்தியா மைய மருந்து அதிகாரம் ஆன் ,சீரம் நிறுவனம் ஆஃப் இந்தியா ,மைய மருந்து அதிகாரம் ,சீரம் நிறுவனம் ,பொருள் நிபுணர் குழு ,